Crispr Therapeutics shares tumble after significant earnings miss
JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a $35 million market cap biotech company, announced Monday the upcoming release of Nugevia PWR, a daily mitochondrial health supplement designed to support cellular energy, endurance, and recovery. According to InvestingPro data, the stock has shown significant volatility, trading at $1.06, well below its 52-week high of $19.51.
The supplement, which combines the company’s proprietary JOTROL resveratrol-based platform with other mitochondrial support ingredients, is expected to be commercially available in Fall 2025.
According to the company’s press release, PWR targets consumer demand for science-backed supplements in the longevity and wellness markets, which are projected to reach $8 trillion by 2030.
"With PWR, we are tapping into the bioenergetic core of healthy aging," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences.
The company stated that JOTROL, which demonstrated a nine-fold increase in resveratrol bioavailability in Phase I trials, is combined with NovaSOL solubilized CoQ10 in the PWR formulation. These ingredients are intended to boost mitochondrial energy output, reduce exercise-related oxidative stress, and support muscle recovery.
PWR will be the second product in Jupiter’s Nugevia supplement line, joining an existing product called GLO. The company described the supplement line as a "high-margin revenue driver" supporting its therapeutic development efforts.
Jupiter Neurosciences is pursuing both consumer supplements and pharmaceutical applications, with its prescription pipeline focused on central nervous system disorders including Parkinson’s disease, for which it is advancing a Phase IIa trial.
The supplement is designed as a two-capsule-per-day regimen, according to the announcement.
In other recent news, Jupiter Neurosciences has announced the commercial release of its Nugevia product line aimed at enhancing longevity, marking a significant step in its strategy to create immediate revenue streams. The Nugevia line, which uses the company’s proprietary JOTROL technology, is designed to improve healthspan and provide mental and metabolic resilience. Jupiter Neurosciences plans to launch Nugevia GLO, a daily skin health supplement, in Fall 2025, further expanding into the consumer wellness market. The supplement combines JOTROL with NovaSOL Astaxanthin and is marketed for consumers seeking skin health solutions.
Jupiter Neurosciences has also appointed Cherry Bekaert LLP as its new auditor following the resignation of Assurance Dimensions, LLC, which ceased its PCAOB registrants practice. Assurance Dimensions’ previous audit reports did not contain adverse opinions but noted uncertainty about the company’s ability to continue as a going concern. The company is progressing with its clinical trials, including a Phase 2a trial for Parkinson’s disease and potential NIH funding for an Alzheimer’s study. Jupiter’s expansion into the longevity market aligns with a projected growth to $8 trillion by 2030, aiming to generate revenue alongside its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.